Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.
- Trial name
- NCT01328379
- Testing
- Dalfampridine-ER 5mg, Dalfampridine-ER 10mg
- Where
- 70 sites in United States
- Volunteers
- 430 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Primary Objective: Assess the antibody response to influenza vaccine in patients with relapsing form of multiple sclerosis (RMS) treated with teriflunomide compared to a reference population.
- Trial name
- TERIVA (NCT01403376)
- Testing
- teriflunomide, Interferon-β-1, Influenza vaccine
- Where
- 14 sites in Austria, Canada and 3 more
- Volunteers
- 128 people
- Sponsor
- Sanofi
Multiple Sclerosis
Relıabılıty and valıdıty of the Two-minute Test wıth Multiple Sclerosis
The study will include 50 MS patients who were examined by a specialist neurologist diagnosed according to McDonalds criteria in the Neurology Outpatient Clinic of SANKO University Sani Konukoğlu Application and Research Hospital…
- Trial name
- NCT06849960
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Sanko University
Multiple Sclerosis
Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Allogeneic human umbilical cord tissue-derived stem cells injected intravenously (IV) once per day for 7 days is a safe and will induce a therapeutic effect in multiple sclerosis (MS) patients.
- Trial name
- NCT02034188
- Testing
- Umbilical cord mesenchymal stem cells
- Where
- Panama
- Volunteers
- 20 people
- Sponsor
- Translational Biosciences
Multiple Sclerosis
Effect of a Mobile Health App on Pain and Quality of Life in Patients With Neuropathic Pain in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, leading to inflammation, neurodegeneration, and a range of physical and invisible symptoms.
- Trial name
- NCT06982742
- Testing
- Mobile Health App for Neuropathic Pain Management in MS
- Where
- Turkey (Türkiye)
- Volunteers
- 56 people
- Sponsor
- Meryem Kocaslan Toran
Multiple Sclerosis
Metacognition Assessment in Patient With Multiple Sclerosis
This study will assessed the level of consciousness of MS patients suffering of cognitive and motor disorders. Understanding the awareness of the disease is crucial to allow better management of these patients.
- Trial name
- METACOGSEP (NCT04240379)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Grenoble
Multiple Sclerosis
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
This is a Phase I, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of single intravenous (IV) administrations of…
- Trial name
- M22 (NCT01803867)
- Testing
- rHIgM22
- Where
- 17 sites in United States
- Volunteers
- 72 people
- Sponsor
- Acorda Therapeutics
Spasticity
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of oral arbaclofen ER tablets in MS patients with spasticity.
- Trial name
- NCT05179577
- Testing
- Arbaclofen
- Volunteers
- 442 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis, Pregnancy
Kesimpta (Ofatumumab) Pregnancy Registry
The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.
- Trial name
- NCT05634967
- Testing
- Kesimpta
- Where
- United States
- Volunteers
- 725 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers.
- Trial name
- NCT07085507
- Testing
- VT7208
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vidya Therapeutics Inc
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Prevalence of Fabry Disease in a Defined Population at Risk - Patients Formerly Diagnosed With Multiple Sclerosis
The association of Multiple Sclerosis (MS) and Fabry disease is known from own clinical experiences as well as from case reports in the literature, where symptoms and suspicious results in the brain MRI led to the misdiagnosis of…
- Trial name
- NCT01271699
- Volunteers
- 250 people
- Sponsor
- CENTOGENE GmbH Rostock
Multiple Sclerosis, Urinary Incontinence
The Effect of Health Belief Model-Based Pelvic Floor Muscle Exercise Training on Urinary Incontinence and Quality of Life in Female Patients With Multiple Sclerosis
The aim of this study is to evaluate the effect of Pelvic Floor Muscle Exercise Training According to the Health Belief Model on Urinary Incontinence and Quality of Life in Female Patients with Multiple Sclerosis.
- Trial name
- NCT06805331
- Testing
- Intervention group(Pelvic Floor Muscle Exercise Training), control group
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Nurgül KAPLAN
Multiple Sclerosis
Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the real-world clinical effectiveness, as measured by the proportion of participants relapsed at 12 months, in participants treated with dimethyl fumarate (DMF).
- Trial name
- EFFECT (NCT02776072)
- Where
- 121 sites in United States, Argentina and 11 more
- Volunteers
- 2,978 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective is to evaluate the safety and tolerability of natalizumab (BG00002, Tysabri®) in the study population (Russian participants with relapsing remitting multiple sclerosis).
- Trial name
- NCT02142205
- Testing
- BG00002
- Where
- 11 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Biogen
Multiple Sclerosis, Depression
Efficacy of MBI for Depressive Symptoms in Patients With MS
Multiple Sclerosis has a great impact on psychological functioning of patients and can be associated with various psychological disorders and symptoms. The most prevalent one is depression, which ranges from 15% to 47%.
- Trial name
- NCT02611401
- Testing
- Mindfulness, Psychoeducation
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- University of Turin, Italy
Multiple Sclerosis, Depression
Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis
Cognitive and emotional disorders are often encountered in multiple sclerosis (MS) cases: depressive and bipolar disorders are twice as frequent as in general population.
- Trial name
- SepDep (NCT02468765)
- Testing
- Neuropsychological and emotional evaluation with monitoring
- Where
- France
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Lille Catholic University
Multiple Sclerosis
DECISIve - DiagnosE Using the Central veIn SIgn v1.0
DECISIve - DiagnosE using the Central veIn SIgn. A prospective diagnostic superiority study comparing T2* MRI and lumbar puncture in patients presenting with possible Multiple Sclerosis
- Trial name
- DECISiVE (NCT05533905)
- Testing
- Lumbar puncture, MRI
- Where
- United Kingdom
- Volunteers
- 113 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Multiple Sclerosis, Neuropathic Pain
OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis
This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis.
- Trial name
- NCT07221799
- Testing
- glibenclamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Maryland, Baltimore
Relapsing-Remitting Multiple Sclerosis
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment
The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple…
- Trial name
- SOLAR (NCT01285401)
- Testing
- VigantOL oil plus interferon beta-1a (Rebif), Interferon beta-1a (Rebif®) alone
- Where
- 38 sites in Austria, Denmark and 10 more
- Volunteers
- 260 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.